Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...

including myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD). In DM1, Avidity Biosciences continues to progress with their Phase 3 ...

Neurotech has appointed Dr Anthony Filippis as its managing director to steer the company as it progresses clinical testing ...

The company has shown promising results in its preclinical and early clinical trials, particularly with its lead program ...

The Dogs for the Disabled charity has secured a brand new premises in Cork - which will slash waiting times for people in ...

Saudi researchers from Qassim University identified Bethlem Myopathy, a rare genetic disorder. The scientific discovery sheds ...

Upon a potential return to the White House, Donald Trump has outlined a series of immediate actions for his first day and second term. These include dismissing legal cases against him, enacting ...

US President-elect Donald Trump demanded Sunday that Republican lawmakers allow him to appoint key officials without a Senate confirmation vote, aiming to block the little remaining power ...

A new mineral discovered recently in an abandoned gold mine in Hungary has been named kanatzidisite in honor of Greek scientist Mercouri Kanatzidis, an inorganic chemist at Northwestern University, ...